University of Liège

Tools4Patient Develops Predictive Model of the Placebo Response in Parkinson's Disease

Retrieved on: 
Friday, September 17, 2021
Department of Neurology, Xuanwu hospital, Clinical trial, Chronic pain, II, Greater Manchester Transport Innovation Fund, Solution, Parkinson's disease, University of Sydney, ESS, Isabella Tree, Center, Samuel, University of Liège, FSS, Doctor of Philosophy, Multimedia, Patient, III, Population, VCU School of Medicine, IV, OA, Disease, Osteoarthritis, Method, Personality, CEO, University, Neurology, Ophthalmology, Placebo, Cros, Risk, Rush University Medical Center, PD, Algorithm, IGAC, Technology, View, MDS, Drug development, Department, Data analysis, INSERM, Pharmacology, Pharmaceutical industry

"Modeling the Placebo Response in Parkinson's Disease" was presented at the International Parkinson and Movement Disorders Society's MDS Congress 2021.

Key Points: 
  • "Modeling the Placebo Response in Parkinson's Disease" was presented at the International Parkinson and Movement Disorders Society's MDS Congress 2021.
  • The predictive, multivariate Placebell model is based on patients' psychological traits and other factors associated with the placebo response (e.g., baseline PD intensity).
  • "The placebo response is a significant barrier to demonstrating efficacy of experimental therapies for Parkinson's disease," says Olivier Rascol, M.D., Ph.D.
  • "This predictive model of the placebo response in Parkinson's disease is an important step forward in managing this issue and accelerating the delivery of medicines to this patient population."

New Research from Burke Neurological Institute Suggests Raising Vitamin B1 Levels May Provide Novel Treatment for Alzheimer’s Disease

Retrieved on: 
Friday, August 20, 2021
Science, Seniors, Research, Pharmaceutical, Health, Mental Health, Consumer, Clinical Trials, Columbia University, Population, APOE, Journal, University, McDowell, Blood, Observation, Institute, Columbia University Irving Medical Center, Thiamine, Disease, Method, Biomarker, Memory, Research, Georgetown University, Amnesia, Genetic testing, PET, American Journal of Alzheimer's Disease & Other Dementias, MCI, Language, Alzheimer's disease, Lenox Hill Hospital, Dementia, Rancho Los Amigos National Rehabilitation Center, Clinical trial, Glucose, CDR, Risk, Attention, AD, PubMed, ADAS, Collaborative writing, Weill Cornell Medicine, FDA, Stroke, Brain, ADAS-Cog, University of Southern California, University of Liège, Albert Einstein College of Medicine, Pharmaceutical industry, Medical imaging

The research was published in the Journal of Alzheimer's Disease and paves the way for a larger clinical trial.

Key Points: 
  • The research was published in the Journal of Alzheimer's Disease and paves the way for a larger clinical trial.
  • Half of the group of 70 participants took 300-mg benfotiamine pills twice daily, while the other half took placebo (inert) pills.
  • The complete clinical trial and research were published in the November 2020 issue of Journal of Alzheimers Disease.
  • The Burke Neurological Institute is based in White Plains, NY, and was established in 1978 by Dr. Fletcher McDowell as a research institute dedicated to finding cures for chronic neurological disabilities.